Amodio et al Supplementary Figure 2 042320 · Amodio et al., Supplementary Figure 2 Actin Actin...
1
Amodio et al., Supplementary Figure 2 Actin Actin NCIH358 RW7213 20% FBS + - + - EGFR HER3 HER2 IP: EGFR Total Lysates NCIH358 RW7213 + - + - 20% FBS MET EGFR IP: EGFR NCIH358 C106 + - + - NCIH358 C106 + - + - Total Lysates A B Supplementary Figure 2: EGFR Immunoprecipitation (IP) assay. Western blot analysis of EGFR dimerization partners upon FBS stimulation. (A) RW7213, (B) C106. NCIH358 NSCLC cell line was included as control. Cetuximab was used to immunoprecipitate EGFR.
Transcript of Amodio et al Supplementary Figure 2 042320 · Amodio et al., Supplementary Figure 2 Actin Actin...
Amodio et al., Supplementary Figure 2
Actin
Actin
NC
IH35
8
RW
7213
20% FBS +- +-
EGFR
HER3
HER2
IP: EGFR
Total Lysates
NC
IH35
8
RW
7213
+- +- 20% FBS
MET
EGFR
IP: EGFR
NC
IH35
8
C10
6
+- +-
NC
IH35
8
C10
6
+- +-
Total Lysates
A B
Supplementary Figure 2: EGFR Immunoprecipitation (IP) assay. Western blot analysis of EGFR dimerization partners upon FBS stimulation. (A) RW7213, (B) C106. NCIH358 NSCLC cell line was included as control. Cetuximab was used to immunoprecipitate EGFR.